Abstract:Abstract Background: Cancer immunotherapy has currently become a highly active research area of oncology and a common treatment strategy for several cancer types. One prominent reason is that the utilized animal models could not accurately predict the of toxic response of human immune system to anti-cancer drug. For improving the safety of immune drug development, it is urgent to establish a predictive nonclinical animal platform that can accurately predict human immune response to the drugs and detect potential unwanted toxicity to human patient will be critical. We have demonstrated a disseminated tumor-bearing humanized mouse model that can evaluate the toxicity and efficacy of bispecific T cell engager (BiTE). In this study, we co-engrafted disseminated and solid tumor cells to the same mice and compared with mice engrafted with disseminated tumor or solid tumor. The purpose is to develop a novel tumor-bearing mouse model that can simultaneously evaluate the long-term efficacy against solid tumors in addition to cytokine level assessment. Method: Epidermal growth factor receptor (EGFR) expressing human triple negative breast cancer MDA-MB-231/Luciferase-2A-GFP (MDA) cell line was utilized to establish solid tumors in mice. The cells were implanted into PBMC humanized NSG-MHC class I/II double knock out (DKO) mice via orthotopic injection into mammary fat pad (MFP). Disseminated MDA cells were injected intravenously (IV) and tumor cells normally colonize in mouse lungs. Following EGFRxCD3 BiTE dosing initiation, tumor burden in MFP and lungs were evaluated via in vivo Xenogen imaging system, and solid tumor volume in MFP was measured 2 to 3 times a week by a digital caliper. To evaluate the toxicity in response to EGFRxCD3 BiTE treatment, human inflammatory cytokine levels was analyzed by BD cytometric bead. Clinical observations and body weight change, and human immune cell activation were evaluated. Result: EGFRxCD3 BiTE treatments significantly inhibited MFP solid tumor growth regardless the presence of IV implanted with MDA cells. EGFRxCD3 BiTE treatment induced elevated human inflammatory cytokines from humanized mice implanted with combined MFP and IV tumors. By comparison, the serum cytokine levels were low in mice implanted with MDA cells via MFP alone, suggesting that disseminated tumor cells are required for cytokine production induced by EGFRxCD3 BiTE. Conclusion: Without disseminated tumor, MFP solid tumor-bearing mice can be served as a model for drug efficacy but did not induce inflammatory cytokines by EGFRxCD3 BiTE treatment. Combination of solid and disseminated tumor models in the same mice provide a new approach for simultaneously evaluating the toxic cytokine release and efficacy of immunotherapy drugs. Citation Format: Guoxiang Yang, Li-Chin Yao, James G. Keck, Mingshan Cheng. Evaluating toxicity and efficacy of bispecific EGFRXCD3 T cell engager in solid tumor-bearing humanized animal model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6718.

Population pharmacokinetic model of ABL001/CTX‐009 (anti‐VEGF/DLL4) in adult cancer patients with solid tumor

Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors

Analyze Impact of Tumor-Associated Kinetics on Antibody Delivery in Solid Tumors with a Physiologically Based Pharmacokinetics/pharmacodynamics Model.

Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors

Population Pharmacokinetic Modeling and Simulation of TQ-B3101 to Inform Dosing in Pediatric Patients With Solid Tumors

Population Pharmacokinetic Modeling of Adavosertib (AZD1775) in Patients with Solid Tumors

Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy

First-in-human, Phase I Study of AK109, an Anti-Vegfr2 Antibody in Patients with Advanced or Metastatic Solid Tumors

A Modified Phase 1 Clinical Trial of Abivertinib (ac0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M-positive Non-Small Cell Lung Cancer

A First-in-human, Phase I, Dose-Escalation Study to Evaluate Pharmacokinetics, Safety, and Tolerability of KD6001, a Novel Anti-Ctla-4 Monoclonal Antibody (mab) in Patients with Advanced Solid Tumors.

Assessing therapeutic window and dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody): Integrating nonclinical and clinical data using mathematical modeling.

Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI-B001, an EGFR/HER3 Bi-specific Monoclonal Antibody.

A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies.

Abstract 7176: Optimization of T cell co-stimulatory agonists: A semi-mechanistic PKPD model integrating drug properties and tumor-immune interactions

Population pharmacokinetics of adebrelimab – Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer

Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer

Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors

Population pharmacokinetics (Pop PK) of MYL-1402O (a proposed biosimilar to bevacizumab) and reference product (Avastin) in patients with nonsquamous non-small cell lung cancer (nsNSCLC).

Abstract 6718: Evaluating toxicity and efficacy of bispecific EGFRXCD3 T cell engager in solid tumor-bearing humanized animal model

Blinatumomab Trimer Formation: Insights From A Mechanistic PKPD Model Into The Implications For Switching From Infusion To Subcutaneous Dosing Regimen

Comprehensive population pharmacokinetic modelling of sugemalimab, an anti‐programmed death‐ligand 1 (PD‐L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I–III studies